Abstract
CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65% of patients and 0% of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.
Original language | English (US) |
---|---|
Pages (from-to) | 359-365 |
Number of pages | 7 |
Journal | Clinical Immunology |
Volume | 127 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2008 |
Keywords
- Antigens
- Autoimmunity
- Diabetes
- Human
- IGRP
- T cells
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology